

Tumor Volume (mm3)
+/- SEM
800
600
400
200
0
6
8
10
12
14
16
18
20
Days Post Inoculation
TGI (%)
Vehicle
Cmpd 1 3mg/kg QD 22
Cmpd 1 10mg/kg QD 45
Cmpd 1 30mg/kg QD 73 1 PR/10
Cmpd 1 1mg/kg BID 52
Cmpd 1 3mg/kg BID 61

FIG. 1A



Tumor Corrected
Body Weight Change (%)
5
0
-5
-10
-15
-20
6
8
10
12
14
16
18
20
Days Post Inoculation
Vehicle
Cmpd 1 3mg/kg QD
Cmpd 1 10mg/kg QD
Cmpd 1 30mg/kg QD
Cmpd 1 1mg/kg BID
Cmpd 1 3mg/kg BID

FIG. 1B



Tumor Volume (mm3)
+/- SEM
2000
1500
1000
500
0
14
16
18
20
22
24
26
28
Days Post Inoculation
Vehicle
Cmpd 1 10mg/kg QD
Ruxolitinib 30mg/kg BID
Cmpd 1 + Ruxolitinib
TGI (%)
24
44
71

FIG. 2A



Tumor Corrected
Body Weight Change (%)
5
0
-5
-10
-15
-20
14
16
18
20
22
24
26
28
Days Post Inoculation
Vehicle
Cmpd 1 10mg/kg QD
Ruxolitinib 30mg/kg BID
Cmpd 1 + Ruxolitinib

FIG. 2B



Tumor Volume (mm3)
+/- SEM
1250
1000
750
500
250
0
13
15
17
19
21
23
25
Days Post Inoculation
Vehicle BID
Cmpd 1 10mg/kg QD
Ruxolitinib 60mg/kg BID
Cmpd 1 + Ruxolitinib
TGI (%)
48
52
53

FIG. 3A



Tumor Corrected
Body Weight Change (%)
5
0
-5
-10
-15
-20
13
15
17
19
21
23
25
Days Post Inoculation
Vehicle BID
Cmpd 1 10mg/kg QD
Ruxolitinib 60mg/kg BID
Cmpd 1 10mg/kg QD +
Ruxolitinib 60mg/kg BID

FIG. 3B



Spleen Weight (g)
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
**
****
Vehicle
Ruxolitinib 60mg/kg BID
Cmpd 1 10mg/kg QD
Combination

FIG. 4A



WBC count (x10^6/mL)
100
80
60
40
20
0
**
Vehicle
Ruxolitinib 60mg/kg BID
Cmpd 1 10mg/kg QD
Combination

FIG. 4B

Table 3

Analyte	Dose	Participant(s)	$C_{max,ss}$ (nM)	T_{max} (h)	$t_{1/2}$ (h)	$C_{min,ss}$ (nM)	$AUC_{ss,0-24}$ (h*nM)	CL_{ss}/F (L/h)	V_z/F (L)
Compound 1 (Parent)	8 mg	N = 10	210 ± 93.2 191 (50.3)	1.00 (1.00, 4.00)	10.7 ± 5.51 9.67 (50.8)	35.5 ± 27.8 27.1 (92.9)	2100 ± 869 1940 (45.1)	10.8 ± 4.99 9.92 (45.1)	150 ± 57.6 138 (46.1)
	12 mg	N = 89	293 ± 113 272 (40.9)	0.50 (2.00, 8.00)	11.0 ± 14.8 9.17 (49.7)	50.6 ± 41.8 39.1 (82.5)	2990 ± 1330 2740 (43.2)	11.4 ± 4.86 10.5 (43.2)	158 ± 99.9 139 (51.2)
	16 mg	N = 7	340 ± 165 310 (47.5)	2.00 (2.00, 4.00)	15.3 ± 9.96 12.8 (71.4)	101 ± 87.5 63.7 (163)	4320 ± 2860 3610 (71.9)	12.6 ± 7.46 10.7 (71.9)	210 ± 72.9 197 (42.9)
	P-values from a 1-Factor ANOVA of log-transformed, dose-normalized data (factor = dose)								
	Dose		0.556	--	--	--	0.915	--	--
	Pairwise p-values from a 1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)								
	8 mg vs 12 mg		0.689	--	--	--	0.685	--	--
	8 mg vs 16 mg		0.298	--	--	--	0.739	--	--
	12 mg vs 16 mg		0.334	--	--	--	0.942	--	--

Note: Values are presented in the format of mean ± SD and geometric mean (CV%) except that T_{max} is reported as median (range).

FIG. 5



610
620
600
100
75
50
25
0
Pred.
Obs.
IC50=202.4nM
Ex vivo c-Myc Inhibition (%)
Css, Avg at 8mg (600)
Css, Avg at 12mg (610)
Css, Avg at 16mg (620)
1
10
100
1000
Plasma Compound 1 Con. (nM)

FIG. 6



1000
100
10
Ex Vivo IC50 (c-Myc inhibition)
8 mg QD
12 mg QD
16 mg QD
Simulated 4 mg QD
Compound 1 Plasma Conc (nM)
0
4
8
Time (hour)

FIG. 7



8 mg
12 mg
16 mg
1.0
0.8
0.6
0.4
0.2
0.0
Probability of Hyper glycaemia
0 700 1400 2100 2800 3500 4200 4900 5600 6300 7000 7700 8400 9100 9800
AUCss (hx nM)
Obs. mean
Obs. response
Pred. mean
Pred. 90% confidence limits

FIG. 8